



March 15, 2023

PeptiDream Inc.
<https://www.peptidream.com>
(Securities Code: 4587 TSE Prime Market)

PeptiDream Announces New Drug Discovery Collaboration Agreement with Ono Pharmaceutical

KANAGAWA, JAPAN –Mar. 15th, 2023 – PeptiDream Inc., a Japan-based biopharmaceutical company (President and CEO: Patrick C. Reid, hereinafter “PeptiDream”) (Tokyo: 4587) today announced a new multi-target Collaboration Agreement with Ono Pharmaceutical Co., Ltd., (“ONO”) for the discovery and development of macrocyclic peptide therapeutics.

Under the terms of the agreement, PeptiDream will use its proprietary Peptide Discovery Platform System (PDPS) technology to identify and optimize macrocyclic peptides against multiple undisclosed targets of interest selected by ONO, and ONO will be responsible for preclinical and clinical development activities.

This Agreement further strengthens the collaborative relationship the two companies have built over the past several years, following the non-exclusive licensing of PeptiDream’s automated PDPS technology platform in March 2021.

Under the terms of the agreement, PeptiDream will receive an undisclosed upfront payment and multi-year research funding from ONO and is eligible for payments based on the achievement of specified preclinical, clinical, regulatory, and commercial sales milestones. In addition, PeptiDream is eligible to receive tiered royalties on net sales of any such products arising from the collaboration.

“We are excited to announce this collaboration with ONO following our non-exclusive Technology License Agreement in March 2021. We believe that through this research collaboration in parallel with the drug discovery research using PDPS which is already in operation at ONO, we will accelerate drug discovery research efforts on several new targets and enable deeper collaboration involving the application of PDPS between the two companies.” said **Keiichi Masuya, Ph.D., Chief Operating Officer, PeptiDream.**

“We appreciate PeptiDream’s automated PDPS platform technology and are pleased to collaborate with PeptiDream in the discovery of novel macrocyclic constrained peptide drugs. We believe that this new collaboration will accelerate our peptide drug discovery efforts and bring innovative drugs for patients” said **Toichi Takino, Ph.D., Senior Executive Officer and Executive Director, Discovery and Research, ONO.**

About PeptiDream Inc.

PeptiDream Inc. (Tokyo Stock Exchange Prime Market 4587) is leading the translation of macrocyclic peptides into a whole new class of innovative medicines to address unmet

medical needs and improve the quality of life of patients worldwide. Founded in 2006, PeptiDream employs its proprietary Peptide Discovery Platform System (PDPS) technology, a state-of-the-art highly versatile discovery platform which enables the production of highly diverse (trillions) non-standard peptide libraries with high efficiency, for the identification of highly potent and selective macrocyclic peptide candidates, which then can be developed into peptide-based, small molecule-based, peptide-drug conjugate (PDC), and multi-functional peptide conjugates (MPC)-based therapeutics and diagnostics. PeptiDream has an extensive global network of discovery and development partners driving the development and commercialization of a broad and diversified pipeline of investigational therapeutics. PeptiDream also markets and sells a number of radiopharmaceutical and radiodiagnostic products in Japan, through its wholly owned subsidiary, PDRadiopharma. PeptiDream is headquartered in Kawasaki, Japan. For more information about our company, science and pipeline, please visit www.peptidream.com.

Inquiries:

PeptiDream Inc.

Contact: Yuko Okimoto, IR & Public Affairs

Email: y-okimoto@peptidream.com